[CAS NO. 152538-59-5] BTG 1640
PRODUCTS SPECIFICATIONS [152538-59-5]
DESCRIPTION [152538-59-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 245.32 |
| Molecular Formula | C15H19NO2 |
| SMILES | CN1[C@H]([C@]2([H])[C@](CCCC2=O)([H])O1)CC3=CC=CC=C3 |
Summary
BTG 1640 (ABIO-08/01) is a potent anxiolytic isoxazoline. BTG 1640 is a selective inhibitor of GABA- and glutamate-gated chloride channels [1] .
IC50 & Target
GABA- and glutamate-gated chloride channels [1]
In Vivo
BTG 1640 (ABIO-08/01) displays an activity at a very low dosage after single intraperitoneal and single oral administration (gavage) in mouse and rat models of anxiety. Chronic administration resulted neither in tolerance development nor in withdrawal symptoms after abrupt discontinuation of treatment (data on file) [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Correll CU, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023 Feb;22(1):48-74.
- [2] Saletu-Zyhlarz GM, et al. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings. Neuropsychobiology. 2009;59(2):100-9.